Fosun Pharmaceuticals (600196.SH) Oxaliplatin Injection Application Approved

Zhitongcaijing · 09/29 09:33

Zhitong Finance App News, Fosun Pharmaceuticals (600196.SH) announced that the company's holding subsidiary Gisme (Wuhan) Pharmaceutical Co., Ltd.'s application for marketing registration of oxaliplatin injections was recently approved by the China Drug Administration.

According to the announcement, the new drug is mainly used in combination with 5-fluorouracil and folic acid (formyltetrahydrogen) for first-line treatment of metastatic colorectal cancer, adjuvant treatment of stage III (Duke's stage) colon cancer after complete removal of the primary tumor, and treatment of locally advanced and metastatic hepatocellular carcinoma (HCC) that is not suitable for surgical resection or topical treatment, and in combination with capecitabine (XELOX) for adjuvant chemotherapy after radical resection in patients with stage II or stage III gastric adenocarcinoma.